Biolight Life Sciences Ltd., of Tel Aviv, Israel, has filed form F-1 with the SEC to raise up to $10 million. The company is focused on the discovery, development and commercialization of products and product candidates, which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm applied to list ordinary shares on the Nasdaq Capital Market, under the symbol BOLT.